Dr Reddy's Laboratories has called off plans to acquire fellow Indian firm JB Chemicals & Pharmaceuticals' prescription pharmaceutical business in Russia and the CIS.
Dr Reddy's Laboratories has called off plans to acquire fellow Indian firm JB Chemicals & Pharmaceuticals' prescription pharmaceutical business in Russia and the CIS.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
Paratek agrees to acquire Optinose in a “take-private” deal valued at $330m, adding chronic rhinosinusitis product Xhance to its antibiotic Nuzyra.
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
